Bristol Projects Opdivo Sales Will Grow Again In 2021

 
• By Mandy Jackson

With new Opdivo/Yervoy combination data in first-line lung cancer, the company expects the PD-1 inhibitor’s growth to go from flat to rising in 2021. Bristol’s and Celgene’s third quarter earnings exceeded expectations and their merger is on track to close this year.

SC1910_Lung Cancer_47781766_1200.jpg
Bristol expects first-line lung cancer to boost Opdivo sales starting in 2021. • Source: Shutterstock

More from Earnings

More from Business